Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2018, provides an overview of the Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline landscape.

This latest pipeline guide Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 6, 51, 54, 1, 2, 58, 12 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 8, 7, 10 and 6 molecules, respectively.

Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Chronic Lymphocytic Leukemia (CLL) - Overview
  3. Chronic Lymphocytic Leukemia (CLL) - Therapeutics Development
  4. Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment
  5. Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development
  6. Chronic Lymphocytic Leukemia (CLL) - Drug Profiles
  7. Chronic Lymphocytic Leukemia (CLL) - Dormant Projects
  8. Chronic Lymphocytic Leukemia (CLL) - Discontinued Products
  9. Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones
  10. Appendix

For more information about this report visit https://www.researchandmarkets.com/research/qmc7hf/chronic?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Leukemia Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Leukemia Drugs